Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib with Trastuzumab and Chemotherapy as Neoadjuvant Therapy for HER2-positive Breast Cancer
NCT06035679Recruiting
- Start
- Aug 2023
- Primary completion
- Nov 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label, single-arm trial of pyrotinib in HER2-positive breast cancer. Primary endpoint: Total Pathological Complete Response Rate. Started Aug 2023; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06035679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06035679.